FOLFOX and bevacizumab

Phase 2Monoclonal antibody

MMemorial Sloan Kettering Cancer Center

FOLFOX and bevacizumab is one of 46 small molecule programs targeting Gastric Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric CancerActive, not recruiting

Locally Advanced Colon CancerTerminated

Gastric CancerPhase 2

Active, not recruiting

Locally Advanced Colon CancerPreclinical

Terminated

Competition

Competitive Landscape

181 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

24 2

Keytruda

Merck & Co.

Phase 3

20 3

Taxotere

AAvyxa

Phase 3

45 4

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

90 5

Avastin

Roche

Phase 3

11 6

Abraxane

Bristol-Myers Squibb

Phase 3

11 7

Cyramza

Eli Lilly

Phase 3

10 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

20 9

Yervoy

Bristol-Myers Squibb

Phase 3

5 10

Lynparza

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Gastric Cancer

NCT04757363

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04757363·39 enrolled

Locally Advanced Colon Cancer1 trial

Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·N/A·NCT00826800·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FOLFOX and bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOLFOX and bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOLFOX and bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: MMemorial Sloan Kettering Cancer Center

FOLFOX and bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Gastric Cancer1 trial

Locally Advanced Colon Cancer1 trial

References

Drug Info

Quick Facts

Related News